Reports

The Industry Reports section of our portal exhibits systematic reports that have been assimilated for your knowledge and orientation with the current supply-demand situation as well as the state of financial proceeds across various spheres of the Pharmaceutical Tech industry.

SymBio Pharmaceuticals Limited (SymBio) is a biopharmaceutical company that conducts research and development, and manufactures new drug candidates. The company develops drug delivery products such as transdermal patch containing granisetron for the treatment of chemotherapy induced nausea or vomiting. It offers products for use in the therapeutic areas of autoimmune,…

Sanofi India Limited (Sanofi India),a subsidiary of Sanofi is a pharmaceutical company that provides medicines for treatment of patients with cardiovascular disease, thrombotic diseases, metabolic disorders, oncology, respiratory, dermatology, anti-infective diseases, orthopedic diseases, gastrointestinal disorders, and central nervous system. The company was formerly known as Aventis Pharma Limited. It offers…

Merrion Pharmaceuticals Plc (Merrion) is a product development company. It offers prescription pharmaceutical products to meet unmet needs in healthcare. The company develops various drug forms including tablets, capsules and injections. Merrion portfolio spans indications for the treatment of diseases such as bone metastases, breast cancer, osteoporosis, prostate cancer and…

Jiangsu Nhwa Pharmaceutical Corporation Ltd. (Jiangsu) is a pharmaceutical company that develops medicine. The company research, develops and manufactures central nervous system medicines. It offers psychiatrical, anesthetic and neurological medicines including anti-anxiety agent, anti-psychopathic drug, antiepileptic drug, anti-depressant, hypnotic, intravenous anesthetics and respiratory excitant. Jiangsu’s products are used in the…

NeuroVive Pharmaceutical AB (NeuroVive) is a pharmaceutical company that offers products for injury. The company research and develops pharmaceuticals to protect mitochondria from post acute traumatic injury. Its drug development technology platform comprises cyclosporine-A for the treatment of acute traumatic conditions. NeuroVive conducts clinical trials of CicloMulsion and NeuroSTAT in…

Approval of KYNAMRO (mipomersen, apoB synthesis inhibitor, homozygous – HoFH; PhIII for heterozygous familial hypercholesterolemia –HeFH, partnered with Sanofi) in US and discounted pricing has removed the overhang of uncertainty.  Upside from the New Orphan Indications with Global Partners (GSK, BIIB, AZN in 2012) and maturing pipeline remains. Successful systemic…

Approval of KYNAMRO (mipomersen, apoB synthesis inhibitor, homozygous – HoFH; PhIII for heterozygous familial hypercholesterolemia –HeFH, partnered with Sanofi) in US and discounted pricing has removed the overhang of uncertainty.  Upside from the New Orphan Indications with Global Partners (GSK, BIIB, AZN in 2012) and maturing pipeline remains. Successful systemic…

Approval of KYNAMRO (mipomersen, apoB synthesis inhibitor, homozygous – HoFH; PhIII for heterozygous familial hypercholesterolemia –HeFH, partnered with Sanofi) in US and discounted pricing has removed the overhang of uncertainty.  Upside from the New Orphan Indications with Global Partners (GSK, BIIB, AZN in 2012) and maturing pipeline remains. Successful systemic…

Approval of KYNAMRO (mipomersen, apoB synthesis inhibitor, homozygous – HoFH; PhIII for heterozygous familial hypercholesterolemia –HeFH, partnered with Sanofi) in US and discounted pricing has removed the overhang of uncertainty.  Upside from the New Orphan Indications with Global Partners (GSK, BIIB, AZN in 2012) and maturing pipeline remains. Successful systemic…

Approval of KYNAMRO (mipomersen, apoB synthesis inhibitor, homozygous – HoFH; PhIII for heterozygous familial hypercholesterolemia –HeFH, partnered with Sanofi) in US and discounted pricing has removed the overhang of uncertainty.  Upside from the New Orphan Indications with Global Partners (GSK, BIIB, AZN in 2012) and maturing pipeline remains. Successful systemic…